Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sulzer Medica

This article was originally published in The Gray Sheet

Executive Summary

Former parent firm Sulzer Ltd. initiates arbitration proceedings against the orthopedics firm seeking to "confirm legal validity and executability of Sulzer Medica's obligation to indemnify Sulzer Ltd." against device-related expenses and damage claims, Sulzer Ltd. says Dec. 20. "Over the past few weeks Sulzer Medica has...repeatedly denied any obligation to indemnify," Sulzer Ltd. claims. Sulzer Medica is seeking to settle claims related to its Inter-Op hip recall and Natural Knee II implant withdrawals via a proposed $783 mil. settlement (1"The Gray Sheet" Dec. 3, 2001, p. 20)...

You may also be interested in...



Sulzer Medica Optimistic That Mediation Agreement Will Prevent Bankruptcy

An agreement attempting to resolve the suit between Sulzer Orthopedics and injured parties through a third party signals a recognition by plaintiffs that the litigation could bankrupt parent Sulzer Medica, according to the Winterhur, Switzerland company

Pandemic Response In US Consumer Health Market: OTC Pain Relief And Cough/Cold Purchases

Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.

venBio Raises $394m To Fund Biopharmas Through Human Proof-Of-Concept

Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.

UsernamePublicRestriction

Register

MT015885

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel